Popular on EntSun
- PsiRyn News: "PsiRyn's New Single 'Sober' Soars to Number 5 on Adult R&B Billboard Charts" - 159
- Peachtree Immediate Care Opens Two New Locations in December - 108
- Webinar Announcement: Navigating the New Investment Adviser AML Mandate: What Steps Should Investment Advisers Be Taking Now?
- Somebody's Husband by Robbi Renee Earns Early Acclaim for Its Powerful Exploration of Love, Loss, and Healing
- The Band Contemporary Releases New Single, "Real," Ushering in 2025 with an Authentic Anthem
- New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects 13+ Million Americans Each Year: NRx Pharma: Stock Symbol:NRXP
- 6x Entertainment Signs T R U V O N N E, Partners with Position Music for Sync Licensing and Co-Publishing Deal
- The Nashville International Chopin Piano Competition Announces Its Second Edition
- Paris Hilton, Congress Praised for Teen Behavioral Treatment Abuse Prevention
- Dr. Cindy Trimm Graces The Cover of KBN Magazine's Winter Issue
Similar on EntSun
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
- Top Book Printer in Central Ohio announces expansion
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- "Cannabis Industry Dream Team" Launches GreenFlow Systems to Revolutionize Manufacturing Standards
- Pawganja Token: Redefining Cryptocurrency with Transparency and Philanthropy
- Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
- LIB: A master of ingenuity in the field of custom test chambers, unlocking unlimited possibilities!
- PRP Aviation Earns Prestigious "Platinum Cirrus Training Center" Designation
Orlance, Inc. awarded RNA Vaccine Development Grant
EntSun News/11030497
SEATTLE, July 10, 2024 ~ Seattle-based biotech company, Orlance, Inc., has recently been granted a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant, worth $300,000 per year for two years, will be used to develop and optimize RNA vaccine formulations using Orlance's needle-free MACH-1™ platform.
The MACH-1 platform aims to enhance the safety, stability, and efficacy of RNA vaccines for infectious diseases such as influenza and Covid-19, as well as cancer immunotherapy applications. This technology represents a significant advancement in RNA vaccine delivery compared to traditional methods.
Unlike traditional lipid nanoparticle (LNP) RNA vaccine formulations that require ultra-cold storage and have been associated with rare adverse events like myocarditis, the MACH-1 platform utilizes dry, stable RNA-coated gold microparticles. These microparticles are propelled directly into the epidermis using a burst of pressurized gas. Once they penetrate the skin's outermost layer, they are taken up by immune cells that reside there.
More on EntSun News
This needle-free and painless delivery system not only ensures better stability at ambient temperatures but also provides significant supply chain advantages in both developed and low-resource settings. Additionally, it can significantly improve patient comfort and compliance associated with discomfort and fear of needle-based injections.
The SBIR-funded project, titled "Gene Gun-delivered RNA vaccines," will be led by Orlance Principal Investigators Hannah Frizzell, PhD and Kenneth Bagley, PhD. The team aims to optimize RNA formulations for MACH-1 gene gun delivery that maximize loading, maintain functional integrity, and ensure stability and immunogenicity. They will also compare the effectiveness of MACH-1 delivered RNA vaccines against traditional LNP/RNA vaccines in inducing immune responses in preclinical models.
Preliminary studies have shown promising results with MACH-1 delivered RNA vaccines achieving comparable immunogenicity to LNP/RNA vaccines with significantly lower doses. Orlance co-founder and CEO, Kristyn Aalto, explains that while mRNA vaccines have shown great potential in recent years, there is still significant work to be done to improve their utility and global health impact.
More on EntSun News
The grant will enable Orlance to conduct crucial preclinical studies and pave the way for subsequent phases of development, ultimately leading to clinical trials. Aalto also mentions that Orlance already has a well-developed MACH-1 DNA vaccine candidate portfolio and offering both DNA and RNA vaccine options allows them to provide ideal solutions for specific indications.
Founded in 2016 as a spin-out from the University of Washington (UW), Orlance is focused on developing next-generation MACH-1 vaccines and cancer immunotherapies. With $13M in SBIR funding awarded to date, the company has made significant progress towards readiness for initial regulatory filings in 2024. They plan to initiate Phase I clinical trials for their lead infectious disease asset in 2025 and are actively partnering with other vaccine developers to develop MACH-1 vaccine and immunotherapy candidates across multiple indications.
Orlance's MACH-1 platform has the potential to revolutionize RNA vaccine delivery, making it safer, more stable, and more effective. With the support of NIH's SBIR grant, Orlance is one step closer to achieving their goal of improving global health through innovative genetic vaccines.
The MACH-1 platform aims to enhance the safety, stability, and efficacy of RNA vaccines for infectious diseases such as influenza and Covid-19, as well as cancer immunotherapy applications. This technology represents a significant advancement in RNA vaccine delivery compared to traditional methods.
Unlike traditional lipid nanoparticle (LNP) RNA vaccine formulations that require ultra-cold storage and have been associated with rare adverse events like myocarditis, the MACH-1 platform utilizes dry, stable RNA-coated gold microparticles. These microparticles are propelled directly into the epidermis using a burst of pressurized gas. Once they penetrate the skin's outermost layer, they are taken up by immune cells that reside there.
More on EntSun News
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- 810 Billiards & Bowling to host 'Football Finale' on Feb. 9
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals
- Black History Trivia Game and Free Teaching Resources Available for Families and Educators
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
This needle-free and painless delivery system not only ensures better stability at ambient temperatures but also provides significant supply chain advantages in both developed and low-resource settings. Additionally, it can significantly improve patient comfort and compliance associated with discomfort and fear of needle-based injections.
The SBIR-funded project, titled "Gene Gun-delivered RNA vaccines," will be led by Orlance Principal Investigators Hannah Frizzell, PhD and Kenneth Bagley, PhD. The team aims to optimize RNA formulations for MACH-1 gene gun delivery that maximize loading, maintain functional integrity, and ensure stability and immunogenicity. They will also compare the effectiveness of MACH-1 delivered RNA vaccines against traditional LNP/RNA vaccines in inducing immune responses in preclinical models.
Preliminary studies have shown promising results with MACH-1 delivered RNA vaccines achieving comparable immunogenicity to LNP/RNA vaccines with significantly lower doses. Orlance co-founder and CEO, Kristyn Aalto, explains that while mRNA vaccines have shown great potential in recent years, there is still significant work to be done to improve their utility and global health impact.
More on EntSun News
- Scythian Returns to the Weinberg Center with High-Energy Roots Music
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- Hot Hollywood Commercial Talent Agent Zoey Allen Comes to the Inland Empire to Interview Actors
The grant will enable Orlance to conduct crucial preclinical studies and pave the way for subsequent phases of development, ultimately leading to clinical trials. Aalto also mentions that Orlance already has a well-developed MACH-1 DNA vaccine candidate portfolio and offering both DNA and RNA vaccine options allows them to provide ideal solutions for specific indications.
Founded in 2016 as a spin-out from the University of Washington (UW), Orlance is focused on developing next-generation MACH-1 vaccines and cancer immunotherapies. With $13M in SBIR funding awarded to date, the company has made significant progress towards readiness for initial regulatory filings in 2024. They plan to initiate Phase I clinical trials for their lead infectious disease asset in 2025 and are actively partnering with other vaccine developers to develop MACH-1 vaccine and immunotherapy candidates across multiple indications.
Orlance's MACH-1 platform has the potential to revolutionize RNA vaccine delivery, making it safer, more stable, and more effective. With the support of NIH's SBIR grant, Orlance is one step closer to achieving their goal of improving global health through innovative genetic vaccines.
0 Comments
Latest on EntSun News
- Barron Ryan Trio Presents "There Arises Light (in the Darkness)" at the Weinberg Center
- New-and-Improved Caribbean-Food Website Dishes Out Free Ground-Shipping Offer; Affiliate Program Garnished with Generous Commission
- 50th Mount Dora Arts Festival set for Feb 1 and 2, 2024
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
- Classic Theatre of Maryland Presents Arthur Miller's The Crucible
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
- Top Book Printer in Central Ohio announces expansion
- Introducing The Magic Story Cloud: A Whimsical Storytelling Adventure for Kids and Families
- Happy New Year 2025, We're Kicking off with BIG ENERGY!!!
- Impro's LA Noir Unscripted at North Coast Repertory Theatre
- 2025 L.A. Whip Conference Canceled
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- "Cannabis Industry Dream Team" Launches GreenFlow Systems to Revolutionize Manufacturing Standards
- Porter Carroll Jr. Brings Dynamic "Evolution of Cabaret" to New Spire Arts
- Pawganja Token: Redefining Cryptocurrency with Transparency and Philanthropy
- Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
- The Best Places to Go in Mexico in 2025
- Nayarit: Mexico's Best-Kept Secret for Fall and Winter Getaways in 2025
- LIB: A master of ingenuity in the field of custom test chambers, unlocking unlimited possibilities!
- Lauren Elaine Unveils 'Technicolor Fairytale' Bridal Collection: A Fusion of Tradition and Whimsy